

Increased acquired protease inhibitor drug resistance mutations in minor HIV-1 quasispecies from infected patients suspected of failing on national second-line therapy in South Africa

Adetayo Emmanuel Obasa (✉ emmanueladety@gmail.com)

Stellenbosch University Faculty of Medicine and Health Sciences <https://orcid.org/0000-0003-0934-9586>

Anoop T Ambikan

Karolinska Institutet

Soham Gupta

Karolinska Institutet

Ujjwal Neogi

Karolinska Institutet

Graeme Brendon Jacobs

Stellenbosch University Faculty of Medicine and Health Sciences

Research article

Keywords: High-throughput sequencing (HTS), boosted protease inhibitors (bPIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), nucleoside reverse transcriptase inhibitors (NRTIs)

Posted Date: June 2nd, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-32105/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published on February 25th, 2021. See the published version at <https://doi.org/10.1186/s12879-021-05905-2>.

Abstract

Background: HIV-1C has been shown to have a greater risk of virological failure and reduced susceptibility towards boosted protease inhibitors (bPIs), a component of second-line combination antiretroviral therapy (cART) in South Africa. This study entailed an evaluation of HIV-1 drug resistance-associated mutations (RAMs) among minor viral populations through high-throughput sequencing genotypic resistance testing (HTS-GRT) in patients suspected of failing on the South African national second-line cART regimen with bPIs.

Methods: During 2017 and 2018, 67 patient samples were selected, of which 56 samples were successfully analyzed. All patients were receiving bPIs as part of their cART. Viral RNA was extracted, and complete *pol* genes were amplified and sequenced using Illumina HiSeq2500, followed by bioinformatics analysis to quantify the RAMs according to the Stanford HIV Drug Resistance Database.

Results: Statistically significantly ($p < 0.001$) higher PI RAMs were observed in minor viral quasispecies (25%; 14/56) compared to nucleoside reverse transcriptase inhibitors (11%; 6/56), non-nucleoside reverse transcriptase inhibitors (9%; 5/56) and integrase inhibitor RAM (4%; 2/56). The majority of the drug resistance mutations in the minor viral quasispecies were observed in the V82A mutation ($n=13$) in protease and K65R ($n=5$), K103N ($n=7$) and M184V ($n=5$) in reverse transcriptase.

Conclusions: HTS-GRT improved the identification of PI and reverse transcriptase inhibitor (RTI) RAMs in second-line cART patients from South Africa compared to the conventional GRT with $\geq 20\%$ used in Sanger-based sequencing. Several RTI RAMs, such as K65R, M184V or K103N and PI RAM V82A, were identified in $< 20\%$ of the population. Deep sequencing could be of greater value in detecting acquired resistance mutations early.

Background

High-throughput sequencing (HTS) has unique advantages and significantly improves sensitivity in quantifying the minority HIV drug-resistant variants within HIV quasispecies [1]. Increased identification of pre-treatment minority drug resistance mutations (DRMs) compared to Sanger-based sequencing genotypic resistance testing (GRT) was reported from both resource-rich and resource-limited settings [2, 3]. The role of minority drug-resistant variants and their clinical consequences in the failure of combination antiretroviral therapy (cART) is debatable. However, the presence of these variants cannot be ignored.

Studies have shown that even in adherent patients, those with pre-existing Y181C mutants have a triple higher risk of virological failure on an efavirenz-based cART regimen [4]. Several studies have shown that minority pre-treatment drug resistance was associated with reduced treatment efficacy for first-generation non-nucleoside reverse transcriptase inhibitors (NNRTIs), but not for rilpivirine and integrase inhibitors (INIs) [3, 5, 6]. In contrast, other studies have indicated that in a population with a relatively low prevalence of DRM, the use of deep sequencing to detect minority HIV-1 DRM has limited clinical benefit

[7]. A more recent study reported that incorporating the minor DRMs might improve the predictive value of GRT, but that very low thresholds of minority mutations can compromise the test specificity [8]. Data on acquired minority mutations on treatment-failure patients are limited.

In sub-Saharan Africa, South Africa has 23.6% pre-treatment drug resistance to efavirenz or NVP, followed by Namibia with 13.8%, while Zimbabwe has 10.9% resistance to NVP [8]. HIV-1 subtype C (HIV-1C) is the major HIV-1 subtype in South Africa, responsible for more than 90% of infections. The recommended second-line cART consists of the nucleoside reverse transcriptase inhibitors (NRTIs) zidovudine or tenofovir and lamivudine and a ritonavir-boosted (/r) protease inhibitor (PI), usually lopinavir (LPV/r) [9, 10]. Earlier study from Sweden and South Africa reported that despite good adherence, there is an increased risk of virological failure in patients with HIV-1C on bPI-based regimens [5, 11]. *Ex vivo* and *in vitro* experiments also indicated large variations in susceptibility of HIV-1C viruses in the absence of PI resistance-associated mutations (RAMs) [12].

Studies have reported that the rates of virological failure on second-line cART are high in resource-limited settings, including South Africa, and are associated with the duration of exposure to previous drug regimens and poor adherence [13], mostly without any protease RAM [14]. In South Africa, with more than 4.5 million HIV-infected individuals accessing cART, approximately 145 000 (~4%) are accessing second-line cART [15]. However, the drug resistance pattern in patients failing on bPIs is limited and often described by GRT through Sanger sequencing [16]. An earlier study with only seven patients indicated the presence of PI RAMs in bPI-failure patients, which was missed by bulk Sanger sequencing [17]. Therefore, the primary aim of the present study was to determine the level and pattern of HIV drug resistance in minor (< 20%) and major viral populations in patients suspected of failing bPIs.

Methods

Ethics statement

The study was approved by the Health Research Ethics Committee of Stellenbosch University, South Africa (N15/08/071). The study was conducted according to the ethical guidelines and principles of the Declaration of Helsinki 2013, the South African Guidelines for Good Clinical Practice and the Medical Research Council Ethical Guidelines for Research. A waiver of written informed consent was awarded to conduct sequence analyses on these samples by the Health Research Ethics Committee of Stellenbosch University, South Africa.

Viral load

HIV-1 viral load was performed using the Abbott m2000sp and the Abbott m2000rt analyzers (Abbott Laboratories, Abbott Park, IL, USA). Viral RNA was isolated from patient samples according to the manufacturer's instructions using the Abbott RealTime HIV-1 Amplification Reagent Kit.

Study design

Plasma samples were obtained from bPIs suspected of failing patients (as referred by the clinician) from the diagnostic section at the Division of Medical Virology, Stellenbosch University, and the South African National Health Laboratory Services (NHLS), and were collected between March 2017 and February 2018 [5, 18]. We excluded patient samples with no previous cART regimen history and patients receiving first-line cART treatment regimens. Patients had their samples submitted for HIV-1 GRT to the NHLS. The NHLS provides routine genotypic antiretroviral drug resistance testing for clinics in the Western Cape, Gauteng and Eastern Cape provinces.

PCR amplification and HTS

Reverse transcriptase PCR (RT-PCR), which consists of cDNA synthesis followed by first-round PCR, was performed using the SuperScript™ III One-Step RT-PCR System with Platinum™ Taq DNA Polymerase (Invitrogen/Life Technology, Cat. No. 12574026) using the primers 1810F (5'-GCTACACTAGAAGAAATGATGACAGCATG-3') and 5220R (5'-CCCTAGTGGGATGTGTACTTCTGA-3'). The second-round nested PCR was performed with 2001F (5'-TGCAGGGCCCCTAGGAAAAAGGGCTGTT-3') and 5087R (5'-ATCCTGTCTACYTGCCACACAAYC-3') primers using the KAPA HiFi HotStart ReadyMix PCR kit. The amplified products were purified using the QIAamp gel extraction kit (Qiagen, Germany). For HTS, the purified amplicons were fragmented, and the library was prepared using NEBNext® Ultra™ DNA Library Prep Kit for Illumina® (New England Biolab, USA) with multiplexed NEB next adaptors. The samples were then pooled together with other unrelated non-viral indexed libraries. Paired end sequences of read length 250 bp were carried out on the Illumina HiSeq2500. The sequences are available in SRA (submission ID: SUB5871663).

Bioinformatics analysis

The raw reads were adapter-trimmed using TrimGalore version 0.6.2, followed by the removal of the low-quality bases (Phred value score <Q30) by Sickle version 1.33. Duplicate reads were removed using FastUniq. The *de novo* assembly was performed using the Iterative Virus Assembler. The processed reads were aligned against individual *pol* gene sequences in very sensitive local mode using Bowtie2 in order to select reads originated from *pol* genes and create a consensus gene. The subtyping was performed using REGA version 3. The selected reads were then aligned against *pol* protein sequences using the BLASTX program from the BLAST package. The best BLASTX hit was chosen for each read for the amino acid counting, which was performed by in-house script. The resistance was interpreted as per the mutation lists provided in the Stanford HIVDB, accessed on 6 January 2019 [19]. The complete script is available in github: https://github.com/neogilab/MiDRMPol_SouthAfrica.

Results

Among the 67 samples sequenced, current treatment regimen data were not available for 11 samples, and therefore they were excluded from further analyses. Among the 56 patients, 5.3% (n = 3) were on boosted ATV, while only one patient was on DRV/r and the rest (93%; n = 52) were receiving LPV/r. The

median (range) viral load was 71 814 (937-5500000) copies/mL. HIV-1 subtyping identified 55 samples as HIV-1C and one as CRF02_AG. The major PIs, NRTI, NNRTI and INI RAMs were observed among 27% (15/56), 57% (32/56), 50% (28/56) and 7% (4/56), respectively (Fig. 1).

Statistically significantly ($p < 0.001$) higher PI RAMs were observed in minor viral quasispecies (25%; 14/56) compared to NRTI (11%; 6/56), NNRTI (9%; 5/56) and INI RAM (4%; 2/56). A total of 41% (23/56) did not have any PI RAMs. The complete mutation profile is presented in the supplementary Table 1. There was no statistical difference in viral load (\log_{10} copies/mL) in patients who only had PI DRM in minor population variants compared to patients who had only DRM in the major viral population [mean (SD): 4.92 (0.74) vs. 4.66 (0.88); $p = 0.43$]. All 56 patients harbored at least one DRM. Most of the DRMs in the minor viral quasispecies were observed in V82A mutation ($n = 13$) in protease and K65R ($n = 5$), K103N ($n = 7$) and M184V ($n = 5$) in reverse transcriptase (Fig. 2). Despite no mention of use of any INIs by the clinical reports, three patient sequences had the Y143R mutation in major viral quasispecies and one in minor viral quasispecies, which confers resistance to raltegravir (RAL). However, resistance to INI inhibitors was low in the settings. The predicted resistance pattern (as per the Stanford HIV Drug Resistance Database [HIVDB]) is given in Fig. 1c. Half (28/56) of the patients had doravirine cross resistance. There were two patients (ZA94 and ZA97) who were resistant to all classes of drugs, indicating the presence of extremely drug-resistant HIV-1 strains in South Africa.

Discussion

HTS assays have an intrinsic capability of detecting minority HIV-1 quasispecies mutation variants before they emerge as a majority variant under selection pressure, which might lead to virological failure. In this study we used HTS to type the DRM in both minor (< 20% of the population) and major (> 20% of the population) viral quasispecies and identified increased PI RAM in minor viral populations. Our study also indicated very low levels of transmitted INI RAMs in patients failing on a bPI-based regimen.

Earlier studies have indicated that PI RAMs were uncommon in patients failing on second-line cART, with only 7% of patients on bPIs showing PI RAMs [20]. A study using Sanger sequencing indicated that 35% of the patients who had PI DRM failed on bPIs. A recent South African study conducted by Cohen et al. showed high-level resistance to LPV/r in 76/339 (22%), while 45/339 (13%) had high-level resistance to atazanavir and 2/339 (0.6%) had high-level resistance to darunavir [21]. Our study also showed that 34% of the patients had major PI RAMs in the major viral population, while 25% of the patients had PI DRM in the minor viral population. All the patients had at least one DRM. As most of the patients had high viral loads, there is a high chance of transmission of DRM if not treated timely. Furthermore, the PI RAMs in the minor viral population can evolve to become the majority under drug selection pressure.

Earlier studies indicated that HIV-1C has reduced susceptibility towards PIs without the emergence of major PI RAM [22] and that there is higher risk of virological failure [11]. Gag mutations can also confer reduced susceptibility towards PIs [23]. Furthermore, a study conducted in Nigeria reported PI RAMs in 62% of patients receiving PI-based second-line cART, with GRT being limited to patients with good

adherence [24]. In East Africa, Inzaule et al.'s [25] study found one or more major PI resistance mutations in 32% of unselected Kenyan patients with second-line ART failure and a median duration on PI-based ART of 3.1 years [25]. Few other observational studies in the African region have reported on ART exhaustion in 9 to 32% of patients failing second-line therapy [26, 27]. Clinical studies also reported that second-line failure was frequent in South African settings [16], which could further increase the chance of transmission of primary DRMs.

Even though there is no indication of the patients being administered RAL, three of the patients in our study harbored Y143R mutation in > 20% of the population. Previous studies on HIV-1C have shown major INI mutations at baseline in less than 5% of patients from Ethiopia (T66I, E138K, Q148R, and Q148H) and South Africa (Q148H, T66S, E92G, S147G, T66A, Y143YF and Y143H) [3, 5, 14]. However, the presence of INI RAMs in minor viral population is deemed not to have any clinical consequences [28].

Conclusion

We show that the use of high-throughput resistance testing for GRT can greatly improve the identification of acquired PI RAMs in bPI-failing patients. Using HTS-GRT, PI RAMs (V82A) and RTI RAMs (K65R, M184V or K103N) were identified in < 20% of the population that Sanger-based sequencing failed to identify, strengthening their role in detecting the acquired mutations early. In resource-limited settings, the use of these high-throughput resistance-testing assays might help in the early detection of minor variants before evolving as a majority variant. Acquired drug resistance poses a significant threat to achieving the WHO/UNAIDS 90-90-90 targets for 2020. A recent WHO report also indicated an alarming surge in drug resistance across Africa. Continuous surveillance, prevention, and monitoring at both minority variant and population-based level are critical to achieving the WHO/UNAIDS 90-90-90 target.

Abbreviations

AEO Adetayo Emmanuel Obasa

ART Antiretroviral therapy

ATV Atazanavir

ATA Anoop Ambikan

BIC Bictegravir

bPI boosted protease inhibitors

BLAST Basic Local Alignment Search Tool

cDNA Complimentary Deoxyribonucleic acid

DNA Deoxyribonucleic acid

DRM Drug resistance mutations

DTG Dolutegravir

EVG Elvitegravir

GBJ Graeme Brendon Jacobs

GRT Genotypic resistance testing

HIVDB Human Immunodeficiency Virus Database

HTS High-throughput sequencing

INI Integrase inhibitors

INSTI Integrase strand transfer inhibitor

NEB New England Biolabs

NHLS National Health Laboratory Services

NNRTI Non-nucleoside reverse transcriptase inhibitors

NRTI Nucleoside reverse transcriptase inhibitors

NVP Nevirapine

PCR Polymerase chain reaction

PI Protease inhibitor

RAL Raltegravir

RAM Resistance-associated mutations

RNA Ribonucleic acid

RT-PCR Reverse Transcriptase Polymerase Chain Reaction

PCR Polymerase Chain Reaction

UN Ujjwal Neogi

SG Soham Gupta

Declarations

Potential conflicts of interest

All authors declare no conflicts of interest

Declarations

None

Ethics approval and consent to participate

The study was approved by the Health Research Ethics Committee of Stellenbosch University, South Africa (N15/08/071). The study was conducted according to the ethical guidelines and principles of the Declaration of Helsinki 2013, the South African Guidelines for Good Clinical Practice and the Medical Research Council Ethical Guidelines for Research. A waiver of written informed consent was awarded to conduct sequence analyses on these samples by the Health Research Ethics Committee of Stellenbosch University, South Africa.

Consent for publish

Not applicable

Availability of data and materials

The raw FASTQ files dataset were deposited to NCBI-SRA. BioProject ID: PRJNA559799.

Competing Interests

The authors declare that they have no competing interests.

Funding

This study was funded by the following: National Research Foundation (NRF) of South Africa, the Poliomyelitis Research Foundation of South Africa and the NHLS Research Trust for studentship bursary. We also thank Stellenbosch University and the Harry Crossley Foundation for additional financial support. UN is supported by a grant from the Swedish Research Council (2017-01330). GBJ is supported through the South African New Generation of Academics Programme (nGAP).

Author contributions

GBJ and UN conceptualized and designed the study. AEO performed laboratory experiments and detailed sequence analyses and wrote and edited the first draft of the manuscript. ATA and SG helped with

detailed statistical analyses and constructed figures. UN wrote the first draft of the manuscript and performed high-throughput sequencing experiments and sequence analyses. GBJ and UN helped with manuscript proofreading and editing. All authors read and approved the final manuscript.

Acknowledgements

We also acknowledge Ms. Mathilda Claassen and Dr Shambhu Prasad Ganeshappa Aralaguppe for sample collection and technical support.

References

1. Ji H, Enns E, Brumme CJ, Parkin N, Howison M, Lee ER, et al. Bioinformatic data processing pipelines in support of next-generation sequencing-based HIV drug resistance testing: the Winnipeg Consensus. *J Int AIDS Soc.* 2018;21:1–14.
2. Derache A, Iwuji CC, Baisley K, Danaviah S, Marcelin AG, Calvez V, et al. Impact of next-generation sequencing defined human immunodeficiency virus pretreatment drug resistance on virological outcomes in the ANRS 12249 treatment-as-prevention trial. *Clin Infect Dis.* 2019;69:207–14.
3. Telele NF, Kalu AW, Gebre-Selassie S, Fekade D, Abdurahman S, Marrone G, et al. Pretreatment drug resistance in a large countrywide Ethiopian HIV-1C cohort: A comparison of Sanger and high-throughput sequencing /631/326/2521 /631/337/151/1431 /38/23 /38/77 /38/90 /14/63 /38/43 /38/47 /42/40 article. *Sci Rep.* 2018;8:1–10.
4. Paredes R, Lalama CM, Ribaud HJ, Schackman BR, Shikuma C, Giguel F, et al. Pre-existing Minority Drug-Resistant HIV-1 Variants, Adherence, and Risk of Antiretroviral Treatment Failure. *J Infect Dis.* 2010;201:100126095936095–000.
5. Obasa AE, Mikasi SG, Brado D, Cloete R, Singh K, Neogi U, et al. Drug Resistance Mutations Against Protease, Reverse Transcriptase and Integrase Inhibitors in People Living With HIV-1 Receiving Boosted Protease Inhibitors in South Africa. *Front Microbiol.* 2020;11 March:1–9.
6. Li JZ, Kozal MJ, Balduin M, Jakobsen MR, Masquelier B, Johnson JA, et al. Low-Frequency HIV-1 Drug Resistance. 2011.
7. Metzner KJ, Scherrer AU, Von Wyl V, Böni J, Yerly S, Klimkait T, et al. Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naïve patients. *Aids.* 2014;28:2231–9.
8. Inzaule SC, Hamers RL, Noguera-Julian M, Casadellà M, Parera M, de Wit TFR, et al. Primary resistance to integrase strand transfer inhibitors in patients infected with diverse HIV-1 subtypes in sub-Saharan Africa. *J Antimicrob Chemother.* 2018;73:1167–72.
9. World Health Organization (WHO). HIV Drug Resistance Report. 2019. <http://scholar.google.com/scholar/Who+hiv+drug+resistance+report+2012>.
10. Meintjes G, Moorhouse MA, Carmona S, Davies N, Dlamini S, Van Vuuren C, et al. Adult antiretroviral therapy guidelines 2017. *South Afr J HIV Med.* 2017;18:24 pages.

11. Häggblom A, Svedhem V, Singh K, Sönnnerborg A, Neogi U. Virological failure in patients with HIV-1 subtype C receiving antiretroviral therapy: an analysis of a prospective national cohort in Sweden. *Lancet HIV*. 2016;3:e166–74.
12. Sutherland KA, Collier DA, Claiborne DT, Prince JL, Deymier MJ, Goldstein RA, et al. Wide variation in susceptibility of transmitted/founder HIV-1 subtype C Isolates to protease inhibitors and association with in vitro replication efficiency. *Scientific Reports*. 2016;6.
13. Ajose O, Mookerjee S, Mills EJ, Boule A, Ford N. Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: A systematic review and meta-analysis. *Aids*. 2012;26:929–38.
14. Brado D, Obasa AE, Ikomey GM, Cloete R, Singh K, Engelbrecht S, et al. Analyses of HIV-1 integrase sequences prior to South African national HIV-treatment program and availability of integrase inhibitors in Cape Town, South Africa. *Sci Rep*. 2018;8:4709. doi:10.1038/s41598-018-22914-5.
15. Moorhouse M, Maartens G, Venter WDF, Moosa MY, Steegen K, Jamaloodien K, et al. Third-Line Antiretroviral Therapy Program in the South African Public Sector: Cohort Description and Virological Outcomes. *J Acquir Immune Defic Syndr*. 2019;80:73–8.
16. Collier D, Iwuji C, Derache A, De Oliveira T, Okesola N, Calmy A, et al. Virological outcomes of second-line protease inhibitor-based treatment for human immunodeficiency virus type 1 in a high-prevalence Rural South African setting: A competing-risks prospective cohort analysis. *Clin Infect Dis*. 2017;64:1006–16.
17. Fisher R, Zyl GU, Van, Travers SAA, Pond LK, Engelbrech S, Murrell B. Deep Sequencing Reveals Minor Protease Resistance Mutations in Patients Failing a Protease Inhibitor Regimen. *J Virol*. 2012;86:6231–7.
18. Obasa AE, Ashokkumar M, Neogi U, Jacobs GB. Mutations in Long Terminal Repeats κ B Transcription Factor Binding Sites in Plasma Virus Among South African People Living with HIV-1. *AIDS Res Hum Retroviruses*. 2019;35:572–6.
19. Rhee S, Fessel WJ, Liu TF, Marlowe NM, Rowland CM, Rode RA, et al. Predictive Value of HIV-1 Genotypic Resistance Test Interpretation Algorithms. *J Infect Dis*. 2009;200:453–63.
20. Wallis CL, Mellors JW, Venter WDF, Sanne I, Stevens W. Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa. *AIDS Res Treat*. 2011;2011:769627.
21. Pillay M, Khan A, Govender K, Chimukangara R, Ellapen MMP. HIV drug resistance in adults failing protease inhibitor (PI)-based antiretroviral therapy (ART) in KwaZulu-Natal. 27th Int Work HIV Drug Resist Treat Strateg. 2018.
22. Sutherland KA, Parry CM, McCormick A, Kapaata A, Lyagoba F, Kaleebu P, et al. Evidence for reduced drug susceptibility without emergence of major protease mutations following protease inhibitor monotherapy failure in the SARA trial. *PLoS One*. 2015;10:1–14.
23. Robert van Domselaar, DT, Njenda R, Rao A, Sönnnerborg, Kamalendra Singh UN. HIV-1 Subtype C with PYxE Insertion Has Enhanced Binding of Gag-p6 to Host Cell Protein ALIX and Increased Replication

Fitness. *J Virol.* 2019;93:1–14.

24. Rawizza HE, Chaplin B, Meloni ST, Darin KM, Olaitan O, Scarsi KK, et al. Accumulation of Protease Mutations among Patients Failing Second-Line Antiretroviral Therapy and Response to Salvage Therapy in Nigeria. *PLoS One.* 2013;8:1–8.
25. Inzaule SC, Hamers RL, Mukui I, Were K, Owiti P, Kwaro D, et al. Emergence of untreatable, multidrug-resistant HIV-1 in patients failing second-line therapy in Kenya. *Aids.* 2017;31:1495–8.
26. Maiga AI, Fofana DB, Cisse M, Diallo F, Maiga MY, Traore HA, et al. Characterization of HIV-1 antiretroviral drug resistance after second-line treatment failure in Mali, a limited-resources setting. *J Antimicrob Chemother.* 2012;67:2943–8.
27. Steegen K, Carmona S, Bronze M, Papathanasopoulos MA, van Zyl G, Goedhals D, et al. Moderate Levels of Pre-Treatment HIV-1 Antiretroviral Drug Resistance Detected in the First South African National Survey. *PLoS One.* 2016;11:e0166305.
28. Nguyen T, Fofana DB, Lê MP, Charpentier C, Peytavin G, Wirden M, et al. Prevalence and clinical impact of minority resistant variants in patients failing an integrase inhibitor-based regimen by ultra-deep sequencing. *J Antimicrob Chemother.* 2018;73:2485–92.

Figures




Figure 1

Percentage prevalence of PI, NRTI, NNRTI and INI RAMs in minor (<20% of the population) and major (≥20% of the population) viral populations alone and together. The RAM in minor viral quasispecies are indicated.




Figure 2

This is a list of supplementary files associated with this preprint. Click to download.

- [Supplimentary.docx](#)